Tag Archives: GERN

Analysts Offer Insights on Healthcare Companies: Geron (NASDAQ: GERN), Revance Therapeutics (NASDAQ: RVNC) and Electrocore (NASDAQ: ECOR)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Geron (GERN – Research Report), Revance Therapeutics (RVNC – Research Report) and Electrocore (ECOR – Research Report) with bullish sentiments. Geron (GERN)

Analysts Offer Insights on Healthcare Companies: Geron (NASDAQ: GERN), Cara Therapeutics (NASDAQ: CARA) and Applied DNA Sciences (NASDAQ: APDN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Geron (GERN – Research Report), Cara Therapeutics (CARA – Research Report) and Applied DNA Sciences (APDN – Research Report) with bullish sentiments.

B.Riley FBR Reaffirms Their Buy Rating on Geron (GERN)

In a report released today, Andrew D’silva from B.Riley FBR maintained a Buy rating on Geron (GERN – Research Report), with a price target of $4.00. The company’s shares closed last Friday at $1.93. According to TipRanks.com, D’silva is a

Analysts Offer Insights on Healthcare Companies: Geron (NASDAQ: GERN) and Zynex (NASDAQ: ZYXI)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Geron (GERN – Research Report) and Zynex (ZYXI – Research Report) with bullish sentiments. Geron (GERN) B.Riley FBR analyst Andrew D’silva maintained

Analysts Are Bullish on These Healthcare Stocks: Geron (GERN), Chiasma (CHMA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Geron (GERN – Research Report) and Chiasma (CHMA – Research Report) with bullish sentiments. Geron (GERN) In a report released today, Andrew

Geron (GERN) Gets a Buy Rating from Needham

Needham analyst Chad Messer reiterated a Buy rating on Geron (GERN – Research Report) today and set a price target of $3.00. The company’s shares closed last Monday at $0.99, close to its 52-week low of $0.98. According to TipRanks.com,